(New York) The New York Stock Exchange moved in scattered order around the balance on Wednesday, the broad index S

The Dow Jones index advanced 0.14%. THE

The broader index is just half a percentage point away from its January 2022 all-time high of 4,796.56 points.

Following the final three trading sessions of the year, the Dow is expected to end 2023 up approximately 13% for the year, with the S

“The day starts with the index S

The bond market, however, was still easing, with yields on ten-year Treasury notes falling to 3.83% from 3.89% the day before.

“For some, geopolitical anxieties in the Middle East are the cause,” suggested Patrick O’Hare of Briefing.com.

However, oil prices were falling.

On the value side, Microsoft was little affected (-0.21%) by the news of a complaint from the daily New York Times against it and that of ChatGPT, the operator of OpenAI.

The newspaper accuses the companies of violating copyright protection by using its articles and the work of its journalists to feed the capabilities of generative artificial intelligence (AI) services.

The shares listed on Wall Street of the Japanese group SoftBank climbed 2.57% after the technology giant announced that it would double its stake in the American telecom operator T-Mobile US (0.15%).

SoftBank gets 48.8 million shares of T-Mobile US worth $7.6 billion, without paying a cent, under a previous deal dating back to the T-Mobile-Sprint merger that was a subsidiary of SoftBank.

The Chinese electric car manufacturer Nio saw its shares slide by almost 2% after the jump the day before (11%) following the presentation of a new vehicle model.

Within the Dow Jones, Apple shares, in slight decline for five sessions, lost another 0.39%.

“The market has grown so much and so quickly that it is possible that it is going through a period of consolidation,” Schwab analysts said.

The securities listed on Wall Street of the Chinese internet and online gaming giants NetEase (-4.40%) and Tencent (-2.70%) were losing ground, after having seriously declined on Friday, following changes to regulations affecting online gaming in China.

The biotech Coherus BioSciences soared 22% to 2.66 dollars after the American health authorities (FDA) approved an element of treatment for the possible infectious side effects of chemotherapies.